Highlights

  • D. Boral Capital reaffirmed its stock rating and maintained a USD 24.00 price objective.
  • Analyst opinions remain mixed, with most ratings clustered around buy classifications.
  • Recent quarterly results showed earnings and revenue above consensus expectations.

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) were recently the subject of updated analyst commentary after D. Boral Capital reiterated its stock rating in a research note issued to investors. The brokerage maintained a price objective of USD 24.00, reflecting its outlook on the biotechnology company following recent developments.

ImmunityBio continues to attract attention from multiple research firms. While D. Boral Capital maintained its stance, other analysts have expressed differing views. Weiss Ratings reaffirmed a “sell (e+)” rating in late December, highlighting a more cautious assessment. In contrast, Jefferies Financial Group increased its price target from USD 8.00 to USD 9.00 and reiterated its existing rating earlier in December.

Based on aggregated analyst data, the stock currently carries a consensus rating of “Moderate Buy.” Among firms actively covering ImmunityBio, four analysts have issued buy ratings, while one has assigned a sell rating. The average price target compiled across analyst reports stands near USD 11.50, indicating a broad range of expectations regarding the company’s valuation.

The latest earnings release added further context to analyst assessments. ImmunityBio reported a quarterly loss of USD 0.07 per share, outperforming the consensus estimate of a USD 0.10 loss. Revenue for the quarter reached USD 32.06 million, marginally exceeding analyst forecasts of USD 31.88 million. For the full year, analysts anticipate the company will report a loss of approximately USD 0.92 per share.

ImmunityBio operates as a clinical-stage biotechnology company focused on developing immunotherapies targeting cancer and infectious diseases. Its research efforts span engineered T cells, natural killer cells, cytokine superagonists, and viral-vectored vaccines, forming the basis of its ongoing clinical programs and long-term strategy.

IBRX closed at USD 2.82 on January 13, 2026.